Physician profile
Manan Patel
NPI 1003074485
$825.94
in general payments reported to CMS, 2019-2025
14 companies · $810 in 2025
The $810 reported for 2025 was more than what 88% of Anatomic Pathology & Clinical Pathology providers received nationally (typical 2025 total: $50.59).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $15.55 · 2025: $810.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $732 · Education: $93.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $731.99 |
| Education | $93.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $161.66 | 2025 | Mako |
| Merck Sharp & Dohme LLC | $125.47 | 2025 | Keytruda, Welireg, Reblozyl |
| Sobi, INC | $108.51 | 2025 | |
| Novartis Pharmaceuticals Corporation | $97.61 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $75.77 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $57.01 | 2025 | Libtayo |
| Daiichi Sankyo INC. | $52.42 | 2025 | Enhertu |
| Teva Pharmaceuticals USA, INC. | $32.17 | 2024-2025 | Uzedy |
| Pfizer INC. | $24.81 | 2025 | |
| Abbvie INC. | $23.76 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.57 | 2025 | |
| Tolmar, INC. | $16.99 | 2025 | Rubraca |
| Pharmaand Gmbh | $16.99 | 2025 | Rubraca |
| Genentech USA, INC. | $15.20 | 2025 | Phesgo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manan Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.